Phentermine/Topiramate (Qsymia) for Chronic Weight Management

October 2014
American Family Physician;10/15/2014, Vol. 90 Issue 8, p576
Academic Journal
The article presents a drug review on the mechanism of action and efficacy of phentermine/topiramate (Qsymia) for chronic weight management. Topics discussed include potential safety issues in using the drug such as nephrolithiasis, cardiac risk, and teratogenicity, common side effects of the drug, how the drug combined with a reduced-calorie diet results in greater weight loss, and the cost of the drug and other anti-obesity medications approved by the U.S. Food and Drug Administration (FDA).


Related Articles

  • Pharmacotherapy for Obesity and Weight Loss. Rhines, Spenser D.; Heins, Jodi R. // South Dakota Medicine;Nov2013, Vol. 66 Issue 11, p471 

    The article focuses on several medications for the treatment of obesity in the U.S. as of November 2013. Topics discussed include the health and economic costs of obesity in the country, prescription medications approved by the U.S. Food and Drug Administration (FDA) for treatment of obesity and...

  • Combination phentermine and topiramate effective obesity therapy.  // Australian Journal of Pharmacy;Oct2011, Vol. 92 Issue 1097, p81 

    The article presents information on an effective treatment of obesity by the controlled-release combination of drugs phentermine and topiramate. As stated, this combination of drugs is expected to be known by a proposed name Qnexa which is not approved by the U.S. Food and Drug Administration...

  • The fat of the matter.  // Nature Medicine;Aug2012, Vol. 18 Issue 8, p1155 

    The author presents his views on the problem of obesity growing worldwide and discusses the changes because of the introduction of two antiobesity drugs by the U.S. Food and Drug Administration (FDA). Two drugs introduced are lorcaserin, is a weight-loss drug developed by Arena Pharmaceuticals...

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Weight Loss.  // Women's Health;Oct2010, Vol. 7 Issue 8, p36 

    This section offers news briefs related to weight loss. A study published in the "Journal of the American Dietetic Association" found that most of the food items advertised on television contain at least three days' worth of fat and sugar. A molecule has been created by scientists that...

  • Referral Sources to a Weight Management Program. Binks, Martin; Mahlen O'Neil, Patrick // JGIM: Journal of General Internal Medicine;Aug2002, Vol. 17 Issue 8, p596 

    OBJECTIVE: To examine the characteristics and outcomes of physician-referred weight management patients relative to self-referred patients. DESIGN: Review of clinic records of all individuals contacting a weight control program during a 2-year period with follow-up throughout consecutive levels...

  • Diet Inc. Gloede, William F. // American Demographics;Dec2003/Jan2004, Vol. 25 Issue 10, p32 

    Focuses on the low-carbohydrates diet program developed by Doctor Robert Atkins. Impact of the Atkins diet on the food pyramid created by the U.S. Food and Drugs Administration; Examples of food products targeted at the low-carbohydrate dieters; Impact of the diet program on weight reduction. ...

  • GreenSelect Phytosome as an Adjunct to a Low-Calorie Diet for Treatment of Obesity: A Clinical Trial. Pierro, Francesco Di; Menghi, Anna Borsetto; Barreca, Angela; Lucarelli, Maurizio; Calandrelli, Andrea // Alternative Medicine Review;Jun2009, Vol. 14 Issue 2, p154 

    A recently developed oral formulation in the form of coated tablets (Monoselect Camellia®) (MonCam) containing highly bioavailable green tea extract (GreenSelect® Phytosome) was tested in obese subjects (n=100) of both genders on a hypocaloric diet. Fifty subjects were assigned to the...

  • FDA Approves Lorcaserin for Treatment of Obesity.  // International Cardiovascular Research Journal;2012, Vol. 6 Issue 2, p66 

    The article reports on the approval of lorcaserin by the U.S. Food and Drug Administration (FDA) for the treatment of obesity as of June 2012.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics